Literature DB >> 29769405

α-Synuclein stimulation of monoamine oxidase-B and legumain protease mediates the pathology of Parkinson's disease.

Seong Su Kang1, Eun Hee Ahn1, Zhentao Zhang1,2, Xia Liu1, Fredric P Manfredsson3, Ivette M Sandoval3, Susov Dhakal4, P Michael Iuvone4, Xuebing Cao5, Keqiang Ye6,7.   

Abstract

Dopaminergic neurodegeneration in Parkinson's disease (PD) is associated with abnormal dopamine metabolism by MAO-B (monoamine oxidase-B) and intracellular α-Synuclein (α-Syn) aggregates, called the Lewy body. However, the molecular relationship between α-Syn and MAO-B remains unclear. Here, we show that α-Syn directly binds to MAO-B and stimulates its enzymatic activity, which triggers AEP (asparagine endopeptidase; legumain) activation and subsequent α-Syn cleavage at N103, leading to dopaminergic neurodegeneration. Interestingly, the dopamine metabolite, DOPAL, strongly activates AEP, and the N103 fragment of α-Syn binds and activates MAO-B. Accordingly, overexpression of AEP in SNCA transgenic mice elicits α-Syn N103 cleavage and accelerates PD pathogenesis, and inhibition of MAO-B by Rasagiline diminishes α-Syn-mediated PD pathology and motor dysfunction. Moreover, virally mediated expression of α-Syn N103 induces PD pathogenesis in wild-type, but not MAO-B-null mice. Our findings thus support that AEP-mediated cleavage of α-Syn at N103 is required for the association and activation of MAO-B, mediating PD pathogenesis.
© 2018 The Authors.

Entities:  

Keywords:  DOPAL; MPTP; delta‐secretase (AEP); neurodegenerative diseases

Mesh:

Substances:

Year:  2018        PMID: 29769405      PMCID: PMC6003650          DOI: 10.15252/embj.201798878

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  61 in total

1.  Mice lacking alpha-synuclein are resistant to mitochondrial toxins.

Authors:  Peter Klivenyi; Donald Siwek; Gabrielle Gardian; Lichuan Yang; Anatoly Starkov; Carine Cleren; Robert J Ferrante; Neil W Kowall; Asa Abeliovich; M Flint Beal
Journal:  Neurobiol Dis       Date:  2005-11-18       Impact factor: 5.996

2.  Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice.

Authors:  Masaki Wakamatsu; Aiko Ishii; Shingo Iwata; Junko Sakagami; Yuriko Ukai; Mieko Ono; Daiji Kanbe; Shin-ichi Muramatsu; Kazuto Kobayashi; Takeshi Iwatsubo; Makoto Yoshimoto
Journal:  Neurobiol Aging       Date:  2006-12-14       Impact factor: 4.673

3.  Induction of C/EBP beta and GADD153 expression by dopamine in human neuroblastoma cells. Relationship with alpha-synuclein increase and cell damage.

Authors:  Cristina Gómez-Santos; Marta Barrachina; Pol Giménez-Xavier; Esther Dalfó; Isidre Ferrer; Santiago Ambrosio
Journal:  Brain Res Bull       Date:  2005-02-15       Impact factor: 4.077

4.  Age-related changes of MAO-A and -B distribution in human and mouse brain.

Authors:  N Mahy; N Andrés; C Andrade; J Saura
Journal:  Neurobiology (Bp)       Date:  2000

Review 5.  Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

Authors:  M B Youdim; M Weinstock
Journal:  Cell Mol Neurobiol       Date:  2001-12       Impact factor: 5.046

6.  Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct.

Authors:  K A Conway; J C Rochet; R M Bieganski; P T Lansbury
Journal:  Science       Date:  2001-11-09       Impact factor: 47.728

7.  Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine in mice.

Authors:  R E Heikkila; A Hess; R C Duvoisin
Journal:  Science       Date:  1984-06-29       Impact factor: 47.728

8.  Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications.

Authors:  Erin H Norris; Benoit I Giasson; Harry Ischiropoulos; Virginia M-Y Lee
Journal:  J Biol Chem       Date:  2003-05-08       Impact factor: 5.157

9.  Inhibition of delta-secretase improves cognitive functions in mouse models of Alzheimer's disease.

Authors:  Zhentao Zhang; Obiamaka Obianyo; Elfriede Dall; Yuhong Du; Haian Fu; Xia Liu; Seong Su Kang; Mingke Song; Shan-Ping Yu; Chiara Cabrele; Mario Schubert; Xiaoguang Li; Jian-Zhi Wang; Hans Brandstetter; Keqiang Ye
Journal:  Nat Commun       Date:  2017-03-27       Impact factor: 14.919

Review 10.  Reactive oxygen species and inhibitors of inflammatory enzymes, NADPH oxidase, and iNOS in experimental models of Parkinson's disease.

Authors:  Sushruta Koppula; Hemant Kumar; In Su Kim; Dong-Kug Choi
Journal:  Mediators Inflamm       Date:  2012-04-22       Impact factor: 4.711

View more
  27 in total

1.  Akt Phosphorylates NQO1 and Triggers its Degradation, Abolishing Its Antioxidative Activities in Parkinson's Disease.

Authors:  Shilin Luo; Seong Su Kang; Zhi-Hao Wang; Xia Liu; Julia X Day; Zhiping Wu; Junmin Peng; Daxiong Xiang; Wolfdieter Springer; Keqiang Ye
Journal:  J Neurosci       Date:  2019-07-29       Impact factor: 6.167

Review 2.  Rasagiline and selegiline modulate mitochondrial homeostasis, intervene apoptosis system and mitigate α-synuclein cytotoxicity in disease-modifying therapy for Parkinson's disease.

Authors:  Makoto Naoi; Wakako Maruyama; Masayo Shamoto-Nagai
Journal:  J Neural Transm (Vienna)       Date:  2020-01-28       Impact factor: 3.575

3.  Suppression of abnormal α-synuclein expression by activation of BDNF transcription ameliorates Parkinson's disease-like pathology.

Authors:  Qianqian Cao; Shilin Luo; Wei Yao; Youge Qu; Nanbu Wang; Jian Hong; Shigeo Murayama; Zhentao Zhang; Jiaxu Chen; Kenji Hashimoto; Qi Qi; Ji-Chun Zhang
Journal:  Mol Ther Nucleic Acids       Date:  2022-06-01       Impact factor: 10.183

4.  Norepinephrine metabolite DOPEGAL activates AEP and pathological Tau aggregation in locus coeruleus.

Authors:  Seong Su Kang; Xia Liu; Eun Hee Ahn; Jie Xiang; Fredric P Manfredsson; Xifei Yang; Hongbo R Luo; L Cameron Liles; David Weinshenker; Keqiang Ye
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

5.  Bioengineered models of Parkinson's disease using patient-derived dopaminergic neurons exhibit distinct biological profiles in a 3D microenvironment.

Authors:  Nicholas J Fiore; Yosif M Ganat; Kapil Devkota; Rebecca Batorsky; Ming Lei; Kyongbum Lee; Lenore J Cowen; Gist Croft; Scott A Noggle; Thomas J F Nieland; David L Kaplan
Journal:  Cell Mol Life Sci       Date:  2022-01-19       Impact factor: 9.261

6.  Tau modification by the norepinephrine metabolite DOPEGAL stimulates its pathology and propagation.

Authors:  Seong Su Kang; Lanxia Meng; Xingyu Zhang; Zhiping Wu; Ariana Mancieri; Boer Xie; Xia Liu; David Weinshenker; Junmin Peng; Zhentao Zhang; Keqiang Ye
Journal:  Nat Struct Mol Biol       Date:  2022-03-24       Impact factor: 18.361

7.  TRH Analog, Taltirelin Protects Dopaminergic Neurons From Neurotoxicity of MPTP and Rotenone.

Authors:  Cong Zheng; Guiqin Chen; Yang Tan; Weiqi Zeng; Qiwei Peng; Ji Wang; Chi Cheng; Xiaoman Yang; Shuke Nie; Yan Xu; Zhentao Zhang; Stella M Papa; Keqiang Ye; Xuebing Cao
Journal:  Front Cell Neurosci       Date:  2018-12-20       Impact factor: 5.505

8.  Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion In Vitro and Delays Its Aggregation in rAAV-Based Rat Models of Parkinson's Disease.

Authors:  Yoshitsugu Nakamura; Shigeki Arawaka; Hiroyasu Sato; Asuka Sasaki; Taro Shigekiyo; Kazue Takahata; Hiroko Tsunekawa; Takeo Kato
Journal:  J Neurosci       Date:  2021-07-21       Impact factor: 6.167

Review 9.  The Mechanism of Asparagine Endopeptidase in the Progression of Malignant Tumors: A Review.

Authors:  Wenrui Zhang; Yingying Lin
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

Review 10.  The Catecholaldehyde Hypothesis for the Pathogenesis of Catecholaminergic Neurodegeneration: What We Know and What We Do Not Know.

Authors:  David S Goldstein
Journal:  Int J Mol Sci       Date:  2021-06-01       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.